跳至主要内容
临床试验/EUCTR2019-002394-59-DK
EUCTR2019-002394-59-DK进行中(未招募)1 期

Medical Cannabis for fibromyalgia - The CANNFIB trialProtocol for a randomized, double-blind, placebo-controlled, parallelgroup,single-center trial

The Parker Institute, Bispebjerg and Frederiksberg Hospital0 个研究点目标入组 200 人开始时间: 2020年7月8日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Informed consent obtained
  • Clinical diagnosis of fibromyalgia according to the American College of
  • Rheumatology (ACR) 1990 criteria
  • Adult individuals (Age =18 years and <75 years)
  • Average pain intensity = 4 on a Numeric Rating Scale (NRS)
  • No use of medical cannabis (THC/CBD) within the last six months
  • Proficiency in spoken Danish language and able to read and write in
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 175
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 25

排除标准

  • On-going participation in other medical trials for pain management of
  • fibromyalgia
  • Diagnosis of Rheumatoid Arthritis or other inflammatory diseases
  • Diagnosis of other serious chronic diseases
  • Impaired liver and kidney function
  • Pregnancy or insufficient anti-conception therapy for female fertile
  • participants
  • Planning pregnancy or insufficient anti-conception use in female fertile
  • partners of male participants
  • Breast feeding
  • Surgery scheduled for the trial period or within 3 months prior to
  • History of or current diagnosis of cancer
  • History of or current epilepsy and seizures
  • History of or major depressive disorder
  • History of a suicide attempt or any suicidal behavior
  • A mental state impeding compliance with the program
  • History of severe psychiatric disorders
  • History of or current abusive behavior of cannabis
  • History of or current abusive behavior of other drugs
  • History of or current abusive behavior of alcohol
  • Severe personality disorder
  • Current use of opioids, opioid antagonists (LDN) or similar strong
  • Allergic reactions to the active ingredients in cannabidiol

研究者

发起方
The Parker Institute, Bispebjerg and Frederiksberg Hospital

相似试验